LLY

1,042.37

+3.33%↑

JNJ

245.35

+1.18%↑

ABBV

228.74

+1.78%↑

NVS

165.1

+1.48%↑

MRK

122.81

+0.45%↑

LLY

1,042.37

+3.33%↑

JNJ

245.35

+1.18%↑

ABBV

228.74

+1.78%↑

NVS

165.1

+1.48%↑

MRK

122.81

+0.45%↑

LLY

1,042.37

+3.33%↑

JNJ

245.35

+1.18%↑

ABBV

228.74

+1.78%↑

NVS

165.1

+1.48%↑

MRK

122.81

+0.45%↑

LLY

1,042.37

+3.33%↑

JNJ

245.35

+1.18%↑

ABBV

228.74

+1.78%↑

NVS

165.1

+1.48%↑

MRK

122.81

+0.45%↑

LLY

1,042.37

+3.33%↑

JNJ

245.35

+1.18%↑

ABBV

228.74

+1.78%↑

NVS

165.1

+1.48%↑

MRK

122.81

+0.45%↑

Начало・Списък с акции・Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

22.49 -1.1

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

21.95

Максимум

22.74

Ключови измерители
By Trading Economics
Приходи	258M 216M
Продажби	280M 459M
P/E Средно за сектора	60.278 110.024
EPS	1.67
Марж на печалбата	47.04
Служители	705
EBITDA	258M 228M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+42.24% upside

Дивиденти
By Dow Jones
Следващи печалби	24.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1B 2.7B
Предишно отваряне	23.59
Предишно затваряне	22.49

Настроения в новините

By Acuity

55%

45%

290 / 351 Класиране в Healthcare

Apellis Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.02.2026 г., 23:55 ч. UTC

Пазарно говорене

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22.02.2026 г., 23:53 ч. UTC

Пазарно говорене

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22.02.2026 г., 23:53 ч. UTC

Пазарно говорене

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22.02.2026 г., 23:51 ч. UTC

Пазарно говорене

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22.02.2026 г., 23:35 ч. UTC

Пазарно говорене

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22.02.2026 г., 23:21 ч. UTC

Печалби

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22.02.2026 г., 23:20 ч. UTC

Печалби

Nickel Industries 2025 Operating Profit US$126.4 Million

22.02.2026 г., 23:19 ч. UTC

Печалби

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22.02.2026 г., 23:19 ч. UTC

Печалби

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22.02.2026 г., 23:18 ч. UTC

Печалби

Nickel Industries Won't Pay a Final Dividend

22.02.2026 г., 23:16 ч. UTC

Печалби

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22.02.2026 г., 21:35 ч. UTC

Печалби

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22.02.2026 г., 21:34 ч. UTC

Печалби

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22.02.2026 г., 21:34 ч. UTC

Печалби

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22.02.2026 г., 21:33 ч. UTC

Печалби

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22.02.2026 г., 21:33 ч. UTC

Печалби

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22.02.2026 г., 21:28 ч. UTC

Печалби

Ampol Final Dividend A$0.60/Share

22.02.2026 г., 21:28 ч. UTC

Печалби

Ampol FY Revenue A$31.37 Billion, Down 10%

22.02.2026 г., 21:28 ч. UTC

Печалби

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22.02.2026 г., 21:28 ч. UTC

Печалби

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21.02.2026 г., 14:31 ч. UTC

Придобивния, сливания и поглъщания

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21.02.2026 г., 05:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

20.02.2026 г., 23:12 ч. UTC

Придобивния, сливания и поглъщания

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20.02.2026 г., 22:12 ч. UTC

Печалби

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

20.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

20.02.2026 г., 21:23 ч. UTC

Печалби

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20.02.2026 г., 21:20 ч. UTC

Пазарно говорене

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20.02.2026 г., 21:01 ч. UTC

Придобивния, сливания и поглъщания

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20.02.2026 г., 20:38 ч. UTC

Пазарно говорене

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Apellis Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

42.24% нагоре

12-месечна прогноза

Среден 31.69 USD 42.24%

Висок 48 USD

Нисък 19 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Apellis Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Apellis Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

290 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.